Email updates

Keep up to date with the latest news and content from BMC Chemical Biology and BioMed Central.

Open Access Research article

Anti-cancer activity of novel dibenzo[b,f]azepine tethered isoxazoline derivatives

Maralinganadoddi Panchegowda Sadashiva1, Basappa23, Shivananju NanjundaSwamy4, Feng Li4, Kanjoormana Aryan Manu4, Murugan Sengottuvelan2, Doddakunche Shivaramu Prasanna1, Nirvanappa Chikkagundagal Anilkumar3, Gautam Sethi4, Kazuyuki Sugahara2 and Kanchugarakoppal Subbegowda Rangappa1*

Author Affiliations

1 Department of Studies in Chemistry, University of Mysore, Mysore, 570006, India

2 Laboratory of Proteoglycan Signalling and Therapeutics, Faculty of Advanced Life Science, Hokkaido University Graduate School of Life Science, Sapporo, 110021, Japan

3 Department of Chemistry, Central College Campus, Bangalore University, Bangalore, 560001, India

4 Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore, 117597

For all author emails, please log on.

BMC Chemical Biology 2012, 12:5  doi:10.1186/1472-6769-12-5

Published: 3 October 2012


Dibenzoazepine (DB) derivatives are important and valuable compounds in medicinal chemistry. The synthesis and chemotherapeutic properties of naturally occurring DBs and different heterocyclic moiety tethered DBs are reported. Herein, we report the DB-fused hybrid structure that containing isoxazolines (DBIs) and their anti-cancer activity, which could throw light on the structural and functional features of new molecules.

The synthesis and characterization of novel ring DB tethered isoxazoline derivatives (DBIs) were carried out. After the detailed structural characterization using 2D-NMR experiments, the compounds were identified as 5-substituted isoxazolines. The effect of newly synthesized DBIs against the invasion of murine osteosarcoma (LM8G7) cells was studied. Among the tested molecules, compound 4g (5-[−3-(4-chlorophenyl)-4,5-dihydroisoxazol-5-yl-methyl]-5 H-dibenzo[b,f]azepine), was found to inhibit the invasion of LM8G7 cells strongly, when compared to other structurally related compounds. Cumulatively, the compound 4g inhibited the invasion MDA-MB-231 cells completely at 10 μM. In addition to anti-invasion property the compound 4g also inhibited the migration of LM8G7 and human ovarian cancer cells (OVSAHO) dose-dependently. Compound 4g inhibited the proliferation of LM8G7, OVSAHO, human breast cancer cells (MCF-7) and human melphalan-resistant multiple myeloma (RPMI8226-LR5) cells that are comparable to cisplatin and suramin.

Dibenzoazepine; Cycloaddition; Isoxazolines; Anticancer agents; ADMET